HOME

JANIS AND FRIENDS HEPATITIS C WEB SITE

 

Hepatitis C Research

Reports from Digestive Disease Week 2003:

Orlando Fl, May 17-22

Studies Found at http://www.hivandhepatitis.com

Index

  Page One :

HCV Quasi-species Dynamics During Pegasys (peginterferon alfa-2a) and Ribavirin Combination Therapy

  Evaluation of the 24-hour Decline in HCV Genotype 1 Viral Load to Predict Response to Pegasys Plus Ribavirin Combination Therapy
  Early Viral Kinetics in Chronic Hepatitis C Virus Genotype 4
  Racial Differences in Risk for Liver Cancer in Patients with HCV-related Cirrhosis
  Racial Differences in Treatment Response to Hepatitis C Virus in a Large Urban Health System
  Interaction of Steatosis and Non-Alcoholic Steatohepatitis (NASH) in Chronic Hepatitis C
  Page Two:

Addition of Amantadine to Peginterferon and Ribavirin Does Not Increase the Efficacy of this Regimen
  Procrit (epoetin alfa) Treatment of Anemic HCV Patients Allows for Maintenance of Ribavirin Dose, Increases Hemoglobin Levels, and Improves Quality of Life
  Aggressive Psychiatric Intervention Based on Clinical Suspicion, Not Standardized Depression Scores, Increases Adherence to Pegylated Interferon and Ribavirin Therapy
  Pegasys (peginterferon alfa-2a) Monotherapy Appears Safe and Effective for Children with Chronic Hepatitis C
  Pharmacokinetics, Pharmacodynamics and Antiviral Response in Patients with Chronic Hepatitis C Infection on Methadone Maintenance Therapy Receiving Pegasys (peginterferon alfa-2a)
  Treatment of Recurrent Hepatitis C After Liver Transplantation with PEG-Intron (peginterferon alfa-2b) Plus Ribavirin: A Preliminary Analysis

Page Three:
  Erythropoietic Response to Anemia is Decreased in Patients Infected With Hepatitis C Virus (HCV) Receiving Combination Ribavirin and PEG-Intron (peginterferon alfa-2b) Therapy
  PEG-Interferon Alfa-2b Plus Ribavirin for Treatment of CHC Patients Who Failed or Relapsed Following Interferon-based Therapy
  Use of Carotenoid-based Functional Food Minimizes the Severity of Ribavirin-related Anemia
  Reasons for Discontinuation for Treatment of Chronic Hepatitis C: Interim Analysis of the Frontier Trial
  Interferon and Interferon Plus Ribavirin in Prevention of Hepatocellular Carcinoma
  Pegylated Interferon Alfa-2b Plus Ribavirin for Prior Nonresponders and Relapsers

Page Four:

 
  Low Dose PEG-Intron Is Equally As Effective As Standard Dose
  Retreatment of Non-responders with PEG-Intron Plus Ribavirin in a Flat and Low Dose Schedule Shows Limited Efficacy
  Preliminary Data Indicate Consensus Interferon Is Effective in Standard Interferon Failures
  Treatment With PEG-Intron and Ribavirin Produces Significant Sustained Virologic Response Rates in HCV Patients who Failed Prior Therapy
  Biopsy vs Non-Biopsy: A Comparison of Cost of Treatment in the Management of Prisoners with Chronic Hepatitis C
  Pegylated Interferon Plus Ribavirin Improves Fibrosis in Non-responders to Standard Interferon Therapy
  Neutropenia Associated with HCV Therapy May Not Be Associated with Serious Adverse Events
  Steatosis Influences the Early Virologic Response Rate in Patients with Chronic Hepatitis C

Page Five:

 
  Comparison of HCV-related Liver Disease Between Caucasians and African Americans
  Prevalence of Hepatitis A, Hepatitis B and HIV Among Hepatitis C Positive State Hospital Patients
  A Proposed New Senate Bill to Protect Millions of Americans with Hepatitis C
  Daily Interferon Plus Ribavirin Is More Effective Than Three Times Weekly Dosing in Genotype 1 HCV Patients But Not in Those with Genotype 2 and 3
  African Americans and Asians with Cirrhosis Have Higher Risk for Liver Cancer
 
  African Americans Failing Treatment with Interferon Monotherapy Are Less Likely to Achieve Sustained Response to Subsequent Retreatments Compared to Caucasians
  Racial Makeup of Patients Determines Response Rates to HCV Treatments
  A Trial of Peginterferon Alfa in Active Ulcerative Colitis
  The Impact of Diabetes on Chronic Hepatitis C
  A Cryocrit Cutoff of 2% Best Predicts Outcome After Liver Transplantation for Hepatitis C
Reviewed Feb 2004